Assessment of the anti-inflammatory and anti-glycemic properties of Royal Jelly and Tocotrienol-rich fraction in an experimental study: Does irisin mediate these effects?

Abstract

Irisin, a novel adipomyokine, has been proposed to be a therapeutic agent against obesity-related metabolic disease. Royal Jelly (RJ) and tocotrienol-rich fraction (TRF) are suggested to promote obesity and its related problems through potential mutual mechanistic pathways. This investigation intended to evaluate the glycemic and inflammation-promoting effects of RJ, TRF, and their combinations to evaluate their synergic effects through irisin action in obese rats induced by a high-fat diet (HFD) that underwent a calorie restriction diet (CRD). Fifty HFD-fed obese rats received the following interventions: RJ, TRF, or RJ + TRF in combination with a CRD for eight consecutive weeks. After the investigation, body weight, fasting blood sugar (FBS), irisin, insulin, C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-1 beta (IL-1β), leptin, adiponectin, and insulin resistance (IR) were assessed. After 8 weeks of treatment, significant weight reduction was noticed in rats that received RJ and RJ + TRF related to the CRD rats (p